Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
J Clin Oncol
2024
42
4
410-420
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.
Br J Cancer
2024
131
2
299-304
Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.
J Clin Oncol
2024
42 Suppl 17_SUPPL
17_SUPPL
LBA4001-LBA4001
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.
npj Precis Oncol
2024
8
1
Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice.
J Clin Invest
2024
134
16
Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.
Hemasphere
2024
8
7
The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities.
Nat. Cancer
2024
5
8
1267-1284
Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis.
Transfusion
2024
64
5
871-880
Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS.
Hemasphere
2024
8
9